GlassScriptPhysician profile
Christopher A Foster
NPI 1285771410
$9,056.41
in general payments reported to CMS, 2019-2025
44 companies · $890 in 2025
The $890 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,846 · 2020: $1,636 · 2021: $1,684 · 2022: $984 · 2023: $1,005 · 2024: $1,012 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,906.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,041.31 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amarin Pharma, INC. | $985.38 | 2019-2022 | |
| Novo Nordisk INC | $958.67 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $815.75 | 2019-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $651.08 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $631.18 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $627.26 | 2019-2024 | Spravato |
| Amgen INC. | $555.60 | 2019-2025 | Otezla, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $439.64 | 2019-2023 | Belsomra, Steglatro, Verquvo |
| Abbvie INC. | $387.43 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $233.21 | 2023-2024 | Quviviq |
| Medicure Pharma INC. | $192.35 | 2020-2023 | Zypitamag |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.35 | 2019-2025 | Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.38 | 2019 | |
| Sumitomo Pharma America, INC. | $110.74 | 2023-2024 | Gemtesa |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.